Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM Patients

Members of the peroxisome proliferator–activated receptor (PPAR) family might be involved in pathologies with altered lipid metabolism. They participate in the control of the expression of genes involved in lipid metabolism and adipocyte differentiation. In addition, thiazolidinediones improve insulin resistance in vivo by activating PPARγ. However, little is known regarding their tissue distribution and relative expression in humans. Using a quantitative and sensitive reverse transcription (RT)-competitive polymerase chain reaction (PCR) assay, we determined the distribution and relative mRNA expression of the four PPARs (α, β, γ1, and γ2) and liver X receptor-α (LXRα) in the main tissues implicated in lipid metabolism. PPARα and LXRα were mainly expressed in liver, while PPARγ1 predominated in adipose tissue and large intestine. We found that PPARγ2 mRNA was a minor isoform, even in adipose tissue, thus causing question of its role in humans. PPARβ mRNA was present in all the tissues tested at low levels. In addition, PPARγ mRNA was barely detectable in skeletal muscle, suggesting that improvement of insulin resistance with thiazolidinediones may not result from a direct effect of these agents on PPARγ in muscle. Obesity and NIDDM were not associated with change in PPARs and LXRα expression in adipose tissue. The mRNA levels of PPARγ1, the predominant form in adipocytes, did not correlate with BMI, leptin mRNA levels, or fasting insulinemia in 29 subjects with various degrees of obesity. These results indicated that obesity is not associated with alteration in PPAR gene expression in abdominal subcutaneous adipose tissue in humans.

[1]  D. Auboeuf,et al.  Acute regulation by insulin of phosphatidylinositol-3-kinase, Rad, Glut 4, and lipoprotein lipase mRNA levels in human muscle. , 1996, The Journal of clinical investigation.

[2]  W. Wahli,et al.  The peroxisome proliferator-activated receptor alpha is a phosphoprotein: regulation by insulin. , 1996, Endocrinology.

[3]  J. Lehmann,et al.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation , 1995, Cell.

[4]  F. Bogazzi,et al.  A novel heterodimerization partner for thyroid hormone receptor. Peroxisome proliferator-activated receptor. , 1994, The Journal of biological chemistry.

[5]  T. Pineau,et al.  Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators , 1995, Molecular and cellular biology.

[6]  K. Umesono,et al.  LXR, a nuclear receptor that defines a distinct retinoid response pathway. , 1995, Genes & development.

[7]  J Auwerx,et al.  The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. , 1996, Biochimica et biophysica acta.

[8]  N. Copeland,et al.  Chromosomal localisation, inducibility, tissue-specific expression and strain differences in three murine peroxisome-proliferator-activated-receptor genes. , 1995, European journal of biochemistry.

[9]  J. Auwerx,et al.  The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue. , 1996, The Journal of clinical investigation.

[10]  J. Tugwood,et al.  A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. , 1996, European journal of biochemistry.

[11]  O. Skraastad.  [Dietary factors and risk of colon cancer]. , 1990, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[12]  P. Arner,et al.  Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? , 1996, Clinical science.

[13]  T. Gramlich,et al.  Dietary Supplementation with Fish Oil in Ulcerative Colitis , 1992, Annals of Internal Medicine.

[14]  O. Mcbride,et al.  cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor. , 1993, Biochemistry.

[15]  B. Spiegelman,et al.  Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor , 1994, Cell.

[16]  J. Clapham,et al.  The thiazolidinedione insulin sensitiser, BRL 49653, increases the expression of PPAR-gamma and aP2 in adipose tissue of high-fat-fed rats. , 1996, Biochemical and biophysical research communications.

[17]  Fabienne,et al.  Differential Expression of Peroxisome Proliferator-Activated Receptors (PPARs): Tissue Distribution of PPAR-a, $3, and -y in the Adult Rat* , 2001 .

[18]  Thorsten Heinzel,et al.  Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.

[19]  B. Spiegelman,et al.  Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. , 1996, The Journal of clinical investigation.

[20]  J. Auwerx,et al.  Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. , 1996, The Journal of clinical investigation.

[21]  K. Umesono,et al.  Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors , 1992, Nature.

[22]  M. D. Leibowitz,et al.  Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. , 1996, Biochemical and biophysical research communications.

[23]  J. Gustafsson,et al.  Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. , 1996, Biochemical and biophysical research communications.

[24]  E. Kraegen,et al.  A New Antidiabetic Agent, BRL 49653, Reduces Lipid Availability and Improves Insulin Action and Glucoregulation in the Rat , 1994, Diabetes.

[25]  M. Campieri,et al.  Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. , 1996, The New England journal of medicine.

[26]  Bruce M. Spiegelman,et al.  Inhibition of Adipogenesis Through MAP Kinase-Mediated Phosphorylation of PPARγ , 1996, Science.

[27]  Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. , 1992, Molecular endocrinology.

[28]  J. Auwerx,et al.  Expression of the Peroxisome Proliferator-activated Receptor Gene Is Stimulated by Stress and Follows a Diurnal Rhythm (*) , 1996, The Journal of Biological Chemistry.

[29]  L. Teboul,et al.  Thiazolidinediones and Fatty Acids Convert Myogenic Cells into Adipose-like Cells (*) , 1995, The Journal of Biological Chemistry.

[30]  M. Rodbell.  The metabolism of isolated fat cells , 1965 .

[31]  D. Auboeuf,et al.  The use of the reverse transcription-competitive polymerase chain reaction to investigate the in vivo regulation of gene expression in small tissue samples. , 1997, Analytical biochemistry.

[32]  M. Maffei,et al.  Positional cloning of the mouse obese gene and its human homologue , 1995, Nature.

[33]  B. Howard,et al.  Dyslipidemia in non-insulin-dependent diabetes mellitus. , 1994, Endocrine reviews.

[34]  K. Umesono,et al.  Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Mukherjee,et al.  The Human Peroxisome Proliferator-activated Receptor (PPAR) Subtype NUC1 Represses the Activation of hPPARα and Thyroid Hormone Receptors (*) , 1995, The Journal of Biological Chemistry.

[36]  D. Noonan,et al.  Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[37]  E. Ravussin,et al.  Leptin levels in human and rodent: Measurement of plasma leptin and ob RNA in obese and weight-reduced subjects , 1995, Nature Medicine.

[38]  W. Wahli,et al.  Peroxisome Proliferator-activated Receptor Mediates Cross-talk with Thyroid Hormone Receptor by Competition for Retinoid X Receptor , 1995, The Journal of Biological Chemistry.

[39]  W. Wahli,et al.  The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.